Neurological complications of the human immunodeficiency virus (HIV) infection;Complicaciones neurológicas de la infección por el virus de la inmunodeficiencia humana

Neurologia

Volumn 22, Issue 5, 2007, Pages 312-319

  Garcia Moncó, Juan Carlos ^a,b   Pinedo Brochado, A ^a   Escalza Cortina, I ^a  

^a HOSPITAL DE GALDAKAO   (Spain)

^b Hospital dc Galdácano   (Spain)

Author keywords

Acquired inmunodeficiency syndrome; CD4 lymphocytes; Human inmunodeficiency virus; Neurological complications

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TINOFOVIR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

BONE MARROW SUPPRESSION; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; DEMENTIA; DIARRHEA; DRUG HYPERSENSITIVITY; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERURICEMIA; IMMUNE DEFICIENCY; LACTIC ACIDOSIS; LYMPHOMA; METABOLIC DISORDER; MIGRAINE; MORTALITY; MYCOSIS; MYOPATHY; NEPHROLITHIASIS; NEUROLOGIC DISEASE; OPPORTUNISTIC INFECTION; PANCREATITIS; PANCYTOPENIA; PERIORAL DERMATITIS; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; RASH; REVIEW; VACCINATION; VIRUS LOAD;

ANTI-HIV AGENTS; DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; NERVOUS SYSTEM DISEASES;

EID: 34347336297     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. st century. N Engl J Med 1999;341:1046-50.
2. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Seines OA, Miller EN, et al. HIV-associated neurologic disease incidence changes: multicenter AIDS Cohort Study, 1990-1998. Neurology 2001; 56:257-60.
3. Dilley JW, Schwarcz S, Loeb L, Hsu L, Nelson K, Scheer S. The decline of incident cases of HIV-associated neurological disorders in San Francisco, 1991-2003. AIDS 2005;19:634-5.
4. Power C, Gill MJ, Johnson RT. Progress in clinical neurosciences: the neuropathogenesis of HIV infection: host-virus interaction and the impact of therapy. Can J Neurol Sci 2002;29:19-32.
5. Samuel R, Bettiker RL, Suh B. AIDS related opportunistic infections, going but not gone. Arch Pharm Res 2002;25:215-28.
6. Pantaleo G, Graziosi C, Fauci AS. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993;328:327-35.
7. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol 2005;4:543-55.
8. Williams K, Westmoreland S, Greco J. Magnetic resonance spectroscopy reveals that activated monocytes contribute to neuronal injury in SIV neuroAIDS. J Clin Invest 2005;115:2534-45.
9. Thompson PM, Dutton RA, Hayashi KM, Toga AW, Lopez OL, Aizenstein HJ, et al. Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline. Proc Natl Acad Sci USA 2005;102:15647-52.
10. Cysique LA, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology 2006;66:1447-50.
11. Dube B, Benton T, Cruess DG, Evans DL. Neuropsychiatric manifestations of HIV infection and AIDS. J Psychiatry Neurosci 2005; 30:237-46.
12. Clifford DB. Neurological complications of HIV infection. En: Noseworthy JH, editor. Neurological therapeutics: principles and practice. London: Martin Dunitz, 2006;1060-73.
13. Simpson DM, Kitch D, Evans SR, McArthur JC, Asmuth DM, Cohen B, et al. HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology 2006;66:1679-87.
14. Brew BJ. The peripheral nerve complications of human immunodeficiency virus (HIV) infection. Muscle Nerve 2003;28:542-52.
15. Luciano CA, Pardo CA, McArthur JC. Recent developments in the HIV neuropathies. Curr Opin Neurol 2003;16:403-9.
16. Antinori A, Larussa D, Cingolani A, Lorenzini P, Bossolasco S, Finazzi MG, et al. Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. Clin Infect Dis 2004;39:1681-91.
17. Skiest DJ. Focal neurological disease in patients with acquired immunodeficiency syndrome. Clin Infect Dis 2002;34:103-15.
18. Skiest DJ, Erdman W, Chang WE, Oz OK, Ware A, Fleckenstein J. SPECT thallium-201 combined with toxoplasma serology for the presumptive diagnosis of focal central nervous system mass lesions in patients with AIDS. J Infect 2000;40:274-81.
19. Cinque P, Bestetti A, Morelli P, Presi S. Molecular analysis of cerebrospinal fluid: potential for the study of HIV-1 infection of the central nervous system. J Neurovirol 2000;6(Suppl. 1):S95-102.
20. Cinque P, Scarpellini P, Vago L, Linde A, Lazzarin A. Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. AIDS 1997;11:1-17.
21. Antinori A, Cingolani A, De Luca A, Gaidano G, Ammassari A, Larocca LM, et al. Epstein-Barr virus in monitoring the response to therapy of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. Ann Neurol 1999;45: 259-61.
22. Bossolasco S, Cinque P, Ponzoni M, Vigano MG, Lazzarin A, Linde A, et al. Epstein-Barr virus DNA load in cerebrospinal fluid and plasma of patients with AIDS-related lymphoma. J Neurovirol 2002;8:432-8.
23. Eberhardt O, Kuker W, Dichgans J, Weller M. HSV-2 sacral radiculitis (Elsberg syndrome). Neurology 2004;63:758-9.
24. Rubin DI. NeuroImages. «Owl's eyes» of CMV ventriculitis. Neurology 2000;54:2217.
25. Mamidi A, DeSimone JA, Pomerantz RJ. Central nervous system infections in individuals with HIV-1 infection. J Neurovirol 2002;8:158-67.
26. Maschke M, Kastrup O, Diener HC. CNS manifestations of cytomegalovirus infections: diagnosis and treatment. CNS Drugs 2002;16:303-15.
27. Cinque P, Baldanti F, Vago L. Ganciclovir therapy for cytomegalovirus (CMV) infection of the central nervous system in AIDS patients: monitoring by CMV DNA detection in cerebrospinal fluid. J Infect Dis 1995;171:1603-6.
28. Safdar A, Rubocki RJ, Horvath JA, Narayan KK, Waldron RL. Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. Clin Infect Dis 2002;35:1250-7.
29. French N, Gray K, Watera C. Cryptoeoccal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002;16:1031-8.
30. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992;326:83-9.
31. García-Moncó JC. Central nervous system tuberculosis. Neurol Clin 1999;17:737-59.
32. García-Moncó JC. CNS Tuberculosis and mycobacteriosis. En: Roos KL, editor. Principles of neurologic infectious diseases. New York: McGraw-Hill, 2005; p. 195-210.
33. García-Moncó JC. Tuberculosis and other mycobacterial infections. En: Noseworthy JH, editor. Neurological therapeutics: principles and practice. London: Martin Dunitz, 2006; p. 1011-20.
34. García-Moncó JC, Ferreira E, Gómez-Beldarrain M. The therapeutic paradox in the diagnosis of tuberculous meningitis. Neurology 2005;65:1991-2.
35. Arroll TW, Centurion-Lara A, Lukehart SA, Van Voorhis WC. T-cell responses to treponema pallidum subsp. pallidum antigens during the course of experimental syphilis infection. Infect Immun 1999;67:4757-63.
36. Rolfs RT, Joesoef MR, Hendershot EF, Rompalo AM, Augenbraun MH, Chiu M, et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. N Engl J Med 1997;337:307-14.
37. Hossain A, Reis ED, Soundararajan K, Kerstein MD, Hollier LH. Nontropical pyomyositis: analysis of eight patients in an urban center. Am Surg 2000;66:1064-6.